Translate page

× To share and enhance best practice management of CML, experts and interested clinicians can discuss difficult or interesting CML cases here. Clinicians submit a brief history of the patient and the case for discussion (no more than 200 words) by posting it in this forum ("+ NEW TOPIC" button below). Please include the country of origin.

Each clinical case will be forwarded to the expert clinical panel for a brief independent response. Consideration should be given to patient confidentiality. Details that are not critical to the case can be changed to preserve anonymity. Please consider including your email with the case. This will not be posted on the website, but is useful should further details be requested by the moderator.

As a full clinical history is necessary for accurate comment, cases and comments on the Forum are ONLY ACCEPTED FROM CLINICIANS. If individual patients have a specific question we encourage them to contact their healthcare provider. General questions can be emailed to info@cml-foundation.org.

DISCLAIMER: The iCMLf does not recommend or endorse any specific tests, physicians, products, procedures, or opinions, and disclaims any representation, warranty, or guaranty as to the same. Reliance on any information provided in this Forum is solely at your own risk.

CML under 18 years old

More
7 years 11 months ago #1001 by mohamad79
I have 3 cases under 18 years with CML

1) A female patient 13 years old not get CCyr after 6 months treatment of Gliveec 400mg/day


2) A male patient 10 years old not get MMR after one year treatment of Gliveec 400mg/day


3) A male patient 11 years old not get MMR after one year treatment of Glivec 400mg/day


as it is known that Tasigna 800mg/day is proved for those who are above 18 years old.


I am asking does any one have that experience dealing with young age group CML patients and help me. I would like to ask if there any research on tasigna given in lower dose 400mg/day in children.

lastly if there are any international research on under 18 year CML patients recieving tasigna, hop to include our patients in it.
  • Meinolf Suttorp
  • Meinolf Suttorp's Avatar
7 years 11 months ago #1002 by Meinolf Suttorp
Replied by Meinolf Suttorp on topic CML under 18 years old
The clinical information on these three cases supported so far is sparse, as no quantitative information is given (minor or partial CCyR?; what is the precise transcript ratio of BCR-ABL1? has this ratio been determined in a certified lab?).
Case 1 has "no CyR" (no cytogenetic response) at months. However, the milestones published by Baccarani et al in 2013 are based on quantitative definitions of failure (failure means less than partial CyR at months 12) and also the pediatric guideline recently published by the I-BFM-consortium (de la Fuente et al. 2014, Br. J. Haematol. 167:33-47) are based on these adult guidelines. Thus, in this case I do not see the need to switch to tasigna, but recommend to repeat the cytogenetics of bone marrow at months 12 and follow the response by regular monitoring of BCR-ABL1 by quantitative PCR at two months intervals from peripheral blood.
Cases 2 and 3 are identical having achieved no major molecular response (MMR = ratio BCR-ABL1/ABL1 <= 0.1%) at months 12. This is suboptimal response as defined (literature see above), but not failure. Without precise quantitative information (is the transcript ratio 45% or is it just 0.2% ?) it is hard to give any recommendation. A switch to tasigna could be recommended, however, the drug is not yet licensed in pediatrics. If prescription without license is possible for children in your country than the dose -as deduced from adults and tolerated so far well in a pediatric trial (see below) -is 2 x daily each 260-300 mg/qm every 12 hours with an empty stomach and no food intake thereafter for another hour. Adults are treated with 2 x 300 mg or 2 x 400 mg. The phase I/II trial on Nilotinib (Tasigna) in children is conducted by Novartis. Please contact the national Novartis country representative to inquire for participation in Novartis trial CAMN 107 A2120. Nilotinib is availiable as capsules with 50 / 200mg strength.
Moderators: Melissa Davis-Bishop